355 related articles for article (PubMed ID: 23847220)
21. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Killick SB; Ingram W; Culligan D; Enright H; Kell J; Payne EM; Krishnamurthy P; Kulasekararaj A; Raghavan M; Stanworth SJ; Green S; Mufti G; Quek L; Cargo C; Jones GL; Mills J; Sternberg A; Wiseman DH; Bowen D
Br J Haematol; 2021 Jul; 194(2):267-281. PubMed ID: 34180045
[No Abstract] [Full Text] [Related]
22. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg PL; Cosler LE; Ferro SA; Lyman GH
J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
[TBL] [Abstract][Full Text] [Related]
23. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
24. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes.
Scott BL; Deeg HJ
Annu Rev Med; 2010; 61():345-58. PubMed ID: 20059342
[TBL] [Abstract][Full Text] [Related]
26. [Current treatment strategies for myelodysplastic syndromes].
Suzuki T
Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
[TBL] [Abstract][Full Text] [Related]
27. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
Lucero J; Al-Harbi S; Yee KWL
Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
30. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
31. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
32. Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa.
Louw VJ; Bassa F; Chan SW; Dreosti L; Du Toit M; Ferreira M; Gartrell K; Gunther K; Jogessar V; Littleton N; Mahlangu J; McDonald A; Patel M; Pool R; Ruff P; Schmidt A; Sissolak G; Swart A; Verburgh E; Webb MJ
S Afr Med J; 2011 Nov; 101(12):900-6. PubMed ID: 22273034
[TBL] [Abstract][Full Text] [Related]
33. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).
Valent P; Wimazal F; Schwarzinger I; Sperr WR; Geissler K
Wien Klin Wochenschr; 2003 Aug; 115(13-14):515-36. PubMed ID: 13677270
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
36. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
37. When to treat myelodysplastic syndromes.
Akhtari M
Oncology (Williston Park); 2011 May; 25(6):480-6. PubMed ID: 21717901
[TBL] [Abstract][Full Text] [Related]
38. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
39. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
